Colorectal liver metastases: Correlations of contrast-enhanced ultrasound features with tumor clinicopathological factors and clinical outcomes following conversion therapy
Restricted accessResearch articleFirst published online April 10, 2024
Colorectal liver metastases: Correlations of contrast-enhanced ultrasound features with tumor clinicopathological factors and clinical outcomes following conversion therapy
To explore the prognostic impact of contrast-enhanced ultrasound (CEUS) features for initially unresectable colorectal liver metastases (CLMs) in a clinical setting of conversion therapy.
METHODS:
Between March 2015 and November 2020, consecutive patients with CLMs who received conversion treatment were prospectively enrolled. All participants underwent liver CEUS at baseline. The primary endpoint was conversion resection rate (R0 and overall resection). Secondary endpoints were objective response rate (ORR), overall survival (OS), and progression-free survival (PFS).
RESULTS:
104 participants who completed conversion treatment were included. CEUS enhancement pattern was correlated with index lesion (size and echogenicity), primary (site, differentiation, perineural invasion, and RAS genotype) and serum (CA19-9 level) characteristics (P = <0.001–0.016). CEUS enhancement pattern was significantly associated with R0 resection rate, ORR, PFS, and OS (P = 0.001–0.049), whereas enhancement degree was associated with PFS and OS (P = 0.043 and 0.045). Multivariate analysis showed that heterogeneous enhancement independently predicted R0 and overall resection (P = 0.028 and 0.024) while rim-like enhancement independently predicted ORR and OS (P = 0.009 and 0.026).
CONCLUSION:
CEUS enhancement pattern was significantly associated with tumor characteristics and clinical outcomes following conversion therapy, and thus might be of prognosis impact for initially unresectable CLMs.
SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, et al.Global Cancer Statistics GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin. 2021;1(3):209–49. doi: 10.3322/caac.21660.
2.
Binder-FoucardF, BossardN, DelafosseP, BelotA, WoronoffAS, RemontetL, et al.Cancer incidence and mortality in France over the 1980–2012 period: solid tumors[J]. Rev Epidemiol Sante Publique. 2014;62(2):95–108. doi: 10.1016/j.respe.2013.11.073.
3.
AbdallaEK, VautheyJN, EllisLM, EllisV, PollockR, BroglioKR, et al.Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases[J]. Ann Surg. 2004;239(6):818–25, 825-7. doi: 10.1097/01.sla.0000128305.90650.71.
4.
AdamR. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases[J]. Ann Oncol. 2003;14Suppl 2:i13–i16. doi: 10.1093/annonc/mdg731.
5.
YeLC, LiuTS, RenL, WeiY, ZhuDX, ZaiSY, et al.Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol. 2013;31(16):1931–8. doi: 10.1200/JCO.2012.44.8308.
6.
TangW, RenL, LiuT, YeQ, WeiY, HeG, et al.Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial[J]. J Clin Oncol. 2020;38(27):3175–84. doi: 10.1200/JCO.20.00174.
7.
OsterlundP, SalminenT, SoveriLM, KallioR, KellokumpuI, LamminmäkiA, et al.Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study[J]. Lancet Reg Health Eur.49. 2021;3:100049. doi: 10.1016/j.lanepe.2021.100049.
8.
AdamR, De GramontA, FiguerasJ, GuthrieA, KokudoN, KunstlingerF, et al.The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. Oncologist. 2012;17(10):1225–39. doi: 10.1634/theoncologist.2012-0121.
9.
DietrichCF, NolsøeCP, BarrRG, BerzigottiA, BurnsPN, CantisaniV, et al.Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J]. Ultrasound Med Biol. 2020;46(10):2579–04. doi: 10.1016/j.ultrasmedbio.2020.04.030.
10.
JungEM, MoranVO, EngelM, Krüger-GengeA, StroszczynskiC, JungF. Modified contrast-enhanced ultrasonography with the new high-resolution examination technique of high frame rate contrast-enhanced ultrasound (HiFR-CEUS) for characterization of liver lesions: First results[J]. Clin Hemorheol Microcirc. 2023;83(1):31–46. doi: 10.3233/CH-221449.
11.
CervantesA, AdamR, RosellóS, ArnoldD, NormannoN, TaïebJ, et al.Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol. 2023;34(1):10–32. doi: 10.1016/j.annonc.2022.10.003.
12.
KongWT, JiZB, WangWP, CaiH, HuangBJ, DingH. Evaluation of Liver Metastases Using Contrast-Enhanced Ultrasound: Enhancement Patterns and Influencing Factors[J]. Gut Liver. 2016;10(2):283–7. doi: 10.5009/gnl14324.
13.
Meitner-SchellhaasB, JesperD, GoertzRS, ZundlerS, StrobelD Washout appearance of hepatocellular carcinomas using standardized contrast-enhanced ultrasound (CEUS) including an extended late phase observation - Real-world data from the prospective multicentre DEGUM study[J]. Clin Hemorheol Microcirc. 2023 Jun 10. doi: 10.3233/CH-231740.
SunY, TongT, CaiS, BiR, XinC, GuY. Apparent Diffusion Coefficient (ADC) value: a potential imaging biomarker that reflects the biological features of rectal cancer[J]. PLoS One. 2014;9(10):e109371. doi: 10.1371/journal.pone.0109371.
16.
Curvo-SemedoL, LambregtsDM, MaasM, BeetsGL, Caseiro-AlvesF, Beets-TanRG. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness[J]. J Magn Reson Imaging. 2012;35(6):1365–71. doi: 10.1002/jmri.23589.
17.
MaoW, ZhouJ, ZhangH, QiuL, TanH, HuY, et al.Relationship between KRAS mutations and dual time point (18)F-FDG PET/CT imaging in colorectal liver metastases[J]. Abdom Radiol (NY). 2019;44(6):2059–66. doi: 10.1007/s00261-018-1740-8.
18.
GruenbergerT, BridgewaterJ, ChauI, García AlfonsoP, RivoireM, MudanS, et al.Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial[J]. Ann Oncol. 2015;26(4):702–8. doi: 10.1093/annonc/mdu580.
19.
LiW, ZhouJ, ZhangT, TaiY, XuY, BaiY, et al.A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases[J]. Am J Cancer Res. 2022;12(4):1648–59.
20.
LineckerM, KuemmerliC, ClavienPA, PetrowskyH. Dealing with insufficient liver remnant: Associating liver partition and portal vein ligation for staged hepatectomy[J]. J Surg Oncol. 2019;119(5):604–12. doi: 10.1002/jso.25435.
21.
HufS, Platz Batista da SilvaN, WiesingerI, HornungM, SchererMN, LangS, et al.Analysis of Liver Tumors Using Preoperative and Intraoperative Contrast-Enhanced Ultrasound (CEUS/IOCEUS) by Radiologists in Comparison to Magnetic Resonance Imaging and Histopathology[J]. Rofo. 2017;189(5):431–40. doi: 10.1055/s-0042-124347.
22.
JonesRP, HamannS, MalikHZ, FenwickSW, PostonGJ, FolprechtG. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer[J]. Eur J Cancer. 2014;50(9):1590–601. doi: 10.1016/j.ejca.2014.02.024.
23.
JooI, LeeJM, KimKW, KlotzE, HanJK, ChoiBI. Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans: evaluation of the hemodynamic features and correlation with the chemotherapy response[J]. Eur J Radiol. 2011;80(3):e278–e283. doi: 10.1016/j.ejrad.2010.12.002.
24.
TranquartF, DujardinPA, BouchéO, MarcusC, BorgC, ManzoniP, et al.Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases. Ultraschall Med. 2018;39:544–58. doi: 10.1055/s-0043-122497.
25.
LiangHY, HuangYQ, YangZX, Ying-Ding, ZengMS, RaoSX. Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases[J]. Eur Radiol. 2016;26(7):2009–18. doi: 10.1007/s00330-015-4043-2.
26.
De BruyneS, Van DammeN, SmeetsP, FerdinandeL, CeelenW, MertensJ, et al.Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases[J]. Br J Cancer. 2012;106(12):1926–33. doi: 10.1038/bjc.2012.184.
27.
DietrichCF, AverkiouMA, CorreasJM, LassauN, LeenE, PiscagliaF. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion[J]. Ultraschall Med. 2012;33(4):344–51. doi: 10.1055/s-0032-1313026.
28.
WiesingerI, JungF, JungEM. Contrast-enhanced ultrasound (CEUS) and perfusion imaging using VueBox®. Clin Hemorheol Microcirc. 2021;78(1):29–40. doi: 10.3233/CH-201040.
29.
HacklC, SchachererD, AndersM, WiedemannLM, MohrA, SchlittHJ, et al.Improved Detection of preclinical Colorectal Liver Metastases by High Resolution Ultrasound including Molecular Ultrasound Imaging using the targeted Contrast Agent BR55[J]. Ultraschall Med. 2016;37(3):290–6. doi: 10.1055/s-0041-111838.
30.
YuanM, LiR, ZhangY, YangL, ZhangX, TangC, et al.Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis[J]. Ultrasound Med Biol. 2019;45(1):26–34. doi: 10.1016/j.ultrasmedbio.2018.08.014.
31.
HarrisGJ, SenagoreAJ, LaveryIC, ChurchJM, FazioVW. Factors affecting survival after palliative resection of colorectal carcinoma[J]. Colorectal Dis. 2002;4(1):31–5. doi: 10.1046/j.1463-1318.2002.00304.x.
32.
de OliveiraCVC, FonsecaGM, KrugerJAP, de MelloES, CoelhoFF, HermanP. Histopathological prognostic factors for colorectal liver metastases: A systematic review and meta-analysis of observational studies[J]. Histol Histopathol. 2021;36(2):159–81. doi: 10.14670/HH-18-274.
33.
LuZ, PengJ, WangZ, PanZ, YuanY, WanD, et al.High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection[J]. Med Oncol. 2016;33(11):121. doi: 10.1007/s12032-016-0838-5.
34.
KimSA, LeeJM, LeeKB, KimSH, YoonSH, HanJK, et al.Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern–correlation with clinicopathologic findings[J]. Radiology. 2011;260(1):148–57. doi: 10.1148/radiol.11101777.
